Literature DB >> 11443182

Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status.

P Szulc1, L C Hofbauer, A E Heufelder, S Roth, P D Delmas.   

Abstract

Previous studies have suggested an important role for androgens and estrogens in bone metabolism in men. However, their local mode of action has not been clearly established. Osteoprotegerin (OPG) is a secreted decoy receptor that inhibits osteoclast formation and activity by neutralizing its cognate ligand. To assess the role of OPG on bone metabolism in men, we conducted a study aimed at evaluating OPG serum levels and their correlation with age, bone mineral density, biochemical markers of bone turnover, and testosterone and estradiol levels in 252 men, aged 19-85 yr. Serum concentrations of OPG increased significantly with age (r = 0.41; P = 0.0001), and were positively correlated with free testosterone index and free estradiol index (r = 0.20; P < 0.002 and r = 0.15; P < 0.03, respectively) after adjustment for age and body weight. Beyond the age of 40 yr, OPG serum concentrations were negatively correlated with urinary excretion of total deoxypyridinoline (r = -0.20; P < 0.01) and PTH serum levels (r = -0.23; P < 0.01). In contrast, there was no correlation with biochemical markers of bone formation, 25-hydroxyvitamin D(3) levels, or bone mineral density at any site. Our data reveal that age as well as androgen and estrogen status are significant positive determinants, whereas PTH is a negative determinant, of OPG serum levels in men. These data suggest that OPG may be an important paracrine mediator of bone metabolism in elderly men and highlight the role of estrogens in the homeostasis of the male skeleton.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443182     DOI: 10.1210/jcem.86.7.7657

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  52 in total

1.  Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.

Authors:  H Dobnig; L C Hofbauer; V Viereck; B Obermayer-Pietsch; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2006-01-25       Impact factor: 4.507

2.  Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  A N Kiani; P Aukrust; T Ueland; I Hollan; E Barr; L S Magder; M Petri
Journal:  Lupus       Date:  2016-12-06       Impact factor: 2.911

Review 3.  Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature.

Authors:  Nicholas G Angelopoulos; Anastasia K Goula; George Papanikolaou; George Tolis
Journal:  Osteoporos Int       Date:  2005-07-05       Impact factor: 4.507

4.  The novel bone alkaline phosphatase B1x isoform in children with kidney disease.

Authors:  Diana Swolin-Eide; Sverker Hansson; Lasse Larsson; Per Magnusson
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

Review 5.  Genetic epidemiology of age-related osteoporosis and its clinical applications.

Authors:  Ching-Lung Cheung; Su-Mei Xiao; Annie W C Kung
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

6.  sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

Authors:  K K Doumouchtsis; A I Kostakis; S K Doumouchtsis; M P Tziamalis; C Tsigris; M A Kostaki; D N Perrea
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

7.  Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.

Authors:  Daniela Hoehn; Jorge E Cortes; L Jeffrey Medeiros; Elias J Jabbour; Juliana E Hidalgo; Rashmi Kanagal-Shamanna; Carlos E Bueso-Ramos
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

Review 8.  Men, bone and estrogen: unresolved issues.

Authors:  E S Orwoll
Journal:  Osteoporos Int       Date:  2003-03-04       Impact factor: 4.507

9.  Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women.

Authors:  M H Gannagé-Yared; M Azoury; I Mansour; R Baddoura; G Halaby; R Naaman
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

10.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.